Samuel L. Aitken, PharmD, MPH

Clinical Pharmacist Specialist
Michigan Medicine
Ann Arbor, MI, United States

Dr. Samuel L. Aitken, PharmD, MPH, BCIDP is a Clincal Pharmacist Specialist in Infectious Diseases at Michigan Medicine. His research focuses on the characterization of multidrug resistant infections in patients with cancer, particularly those with leukemia, incorporating whole-genome sequencing and clinical data to understand both the scope and impact of resistance in this vulnerable population. Dr. Aitken is president-elect of the Society of Infectious Diseases Pharmacists (SIDP).

Disclosure(s): Basilea: Advisor/Consultant; bioMerieux: Advisor/Consultant; Melinta: Advisor/Consultant; Shionogi: Advisor/Consultant

Presentation(s):

• 311 - Defining the magnitude of desirability of outcome ranking (DOOR) differences in effectiveness of Ceftazidime-Avibactam (CZA) versus Ceftolozane-Tazobactam (C/T) for multidrug-resistant (MDR) Pseudomonas aeruginosa infections in the United States (CACTUS)

  Friday, October 18, 2024
  10:42 AM – 10:54 AM US PT

• 312 - Impact of Patient Subgroups on the Efficacy of Ceftazidime-Avibactam (CZA) versus Ceftolozane-Tazobactam (C/T) for Multidrug-resistant (MDR) Pseudomonas aeruginosa infections in the United States (CACTUS)

  Friday, October 18, 2024
  10:54 AM – 11:06 AM US PT